Physician profile
Wayne C Chen
NPI 1679640841
$4,897.64
in general payments reported to CMS, 2019-2025
34 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $156 · 2022: $539 · 2023: $762 · 2024: $1,064 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544 · Education: $46.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.08 |
| Education | $46.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $789.16 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $486.00 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.86 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $291.17 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $256.83 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $243.54 | 2019-2025 | Omvoh |
| Gilead Sciences, INC. | $234.00 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $232.70 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $217.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $190.87 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $167.22 | 2019-2025 | Amjevita, Avsola, Uplizna |
| Exact Sciences Corporation | $161.85 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $149.77 | 2025 | Zenpep |
| Celgene Corporation | $134.63 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $121.49 | 2025 | Sucraid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $73.89 | 2023-2024 | Hyrimoz |
| Pfizer INC. | $70.36 | 2019 | |
| Astellas Pharma US INC | $70.10 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $61.75 | 2023-2024 | Linzess |
| Teleflex LLC | $55.17 | 2022 | |
| Ferring Pharmaceuticals INC. | $53.61 | 2023-2024 | Rebyota |
| Celltrion USA INC. | $52.51 | 2024-2025 | Vegzelma, Zymfentra |
| Medtronic, INC. | $47.59 | 2022-2023 | Interstim |
| Novartis Pharmaceuticals Corporation | $41.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $40.58 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $36.32 | 2022-2023 | Breztri |
| Axonics, INC. | $26.82 | 2022 | |
| Novo Nordisk INC | $24.05 | 2019 | |
| Genentech USA, INC. | $18.19 | 2019 | |
| Medtronic Vascular, INC. | $16.68 | 2020 | |
| Braintree Laboratories, INC. | $15.61 | 2025 | Suflave, Sutab |
| Integra Lifesciences Corporation | $14.85 | 2019 | |
| Currax Pharmaceuticals LLC | $14.59 | 2020 | |
| Shionogi INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.